Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of drugs that inhibit B cell receptor activation, FC-γ receptor signaling, and osteoclast proliferation. Following on approval for treatment of hematologic malignancies, BTK inhibitors are now under investigation to treat a number of di...

Descripción completa

Detalles Bibliográficos
Autores principales: Arneson, Laura C, Carroll, Kristen J, Ruderman, Eric M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409514/
https://www.ncbi.nlm.nih.gov/pubmed/34485183
http://dx.doi.org/10.2147/ITT.S288550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409514/
https://www.ncbi.nlm.nih.gov/pubmed/34485183
http://dx.doi.org/10.2147/ITT.S288550

Ejemplares similares